|
New Treatment Option for Behçet’s Disease
|
On Friday, the U.S. Food and Drug Administration approved apremilast (Otezla, Celgene) for the treatment of oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory condition that affects approximately five in 100,000 people in the U.S.
|
|
Read more
|
|
|
|
Apremilast Improves Joint And Skin Involvement In Psoriatic Arthritis
|
| Apremilast may represent a new oral treatment option for patients with psoriatic arthritis (PsA) and current skin involvement, according to a new study. |
|
Read more
|
|
|
|
EULAR Updates Guidelines for Large Vessel Vasculitis
|
| The European League Against Rheumatism has updated treatment guidelines for the management of large vessel vasculitis. Among the changes, the task force no longer recommends the routine use of antiplatelet or anticoagulant therapy. Learn more in this slideshow. |
|
Read more
|
|
|
